The impact of centralised care of younger AML patients on treatment results: a retrospective analysis of real-world data from a national population-based registry

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Přírodovědeckou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	SEMERAD Lukas SUSTKOVA Zuzana CETKOVSKY Petr JINDRA Pavel KORISTEK Zdenek NOVAK Jan RACIL Zdenek SZOTKOWSKI Tomas WEINBERGEROVA Barbora ZAK Pavel POSPÍŠIL Zdeněk BARANOVA Jana MAYER Jiri
Rok publikování	2021
Druh	Článek v odborném periodiku
Časopis / Zdroj	Acta Oncologica
Fakulta / Pracoviště MU	Přírodovědecká fakulta
Citace
www	https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1917002
Doi	http://dx.doi.org/10.1080/0284186X.2021.1917002
Klíčová slova	ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; HOSPITAL VOLUME; MORTALITY; CHEMOTHERAPY; OUTCOMES
Popis	The care for younger patients with acute myeloid leukaemia (AML) requires fully equipped medical facilities that have routine experience with the management of this aggressive disorder. Two independent analyses of real-world data from the United States (US) have showed a lower early mortality after an intensive chemotherapy when the patients are treated in high-volume centres or in National Cancer Institution-Designated Cancer Centres (NCI-CC) compared to the treatment in low-volume or in non-NCI-CC centres [1,2].